People: Supergen Inc (SUPG.O)

SUPG.O on Consolidated Issue listed on NASDAQ Global Market

2.82USD
9 Feb 2010
Price Change (% chg)

$0.08 (+2.92%)
Prev Close
$2.82
Open
--
Day's High
$2.83
Day's Low
$2.72
Volume
803,943
Avg. Vol
431,702
52-wk High
$3.30
52-wk Low
$1.54

view people for:

Summary

Name Age Since Current Position
Manuso, James 60 2008 Chairman of the Board, President, Chief Executive Officer
Molkentin, Michael 54 2003 Chief Financial Officer, Corporate Secretary
Azab, Mohammad 51 2009 Chief Medical Officer
Girardi, Thomas 69 2000 Director
Lack, Walter 61 2000 Director
Young, Michael 69 2002 Director
Casamento, Charles 63 2007 Director
Goldberg, Allan 67 2005 Director
» Insider Trading

Biographies

Name Description
Manuso, James Dr. James S. J. Manuso, Ph.D. is Chairman of the Board, President and Chief Executive Officer of SuperGen Inc. Dr. Manuso is co-founder and immediate past president and chief executive officer of Galenica Pharmaceuticals, Inc. Dr. Manuso co-founded and was general partner of PrimeTech Partners, a biotechnology venture management partnership, from 1998 to 2002, and managing general partner of The Channel Group LLC. He was also president of Manuso, Alexander & Associates, Inc. Dr. Manuso was a vice president and director of Health Care Planning and Development for The Equitable Companies. He currently serves on the boards of Merrion Pharmaceuticals Ltd. (MERR:IEX; Dublin, Ireland), Novelos Therapeutics, Inc. (NVLT:OB) and privately-held KineMed, Inc. Previously, he served on the boards of Inflazyme Pharmaceuticals, Inc., Symbiontics, Inc., Quark Biotech, Inc., Galenica Pharmaceuticals, Inc., and Supratek Pharma, Inc. Dr. Manuso earned a B.A. with Honors in Economics and Chemistry from New York University, a Ph.D. in Experimental Psychophysiology from the Graduate Faculty of The New School University, a Certificate in Health Systems Management from Harvard Business School, and an Executive M.B.A. from Columbia Business School. Dr. Manuso is the author of over 30 chapters, articles and books on topics including health care cost containment and biotechnology company management. He has taught and lectured at Columbia, New York University, Georgetown, Polytechnic University, and Waseda University (Japan). He has delivered invited addresses at meetings of the American Management Association, the American Medical Association, the Securities Industry Association, the Biotechnology Industry Organization, and many other professional associations. Dr. Manuso previously served as vice president and a member of the Board of Trustees of the Greater San Francisco Bay Area Leukemia & Lymphoma Society.
Molkentin, Michael Mr. Michael Molkentin joined Supergen Inc. as Chief Financial Officer and Corporate Secretary in October 2003. Prior to joining the company, Mr. Molkentin served as interim chief financial officer at Aradigm Corporation from May 2000 to September 2002. From January 1995 to April 2000, Mr. Molkentin served as division controller for Thermo Finnigan Corporation, a subsidiary of Thermo Electron. Mr. Molkentin served in a variety of financial management positions with technology companies, including field controller of Vanstar Corporation, controller of Republic Telcom Systems, Inc. and corporate controller of Computer Automation, Inc. Mr. Molkentin is a CPA and received a B.B.A. in accounting from Bernard M. Baruch College in New York City, New York.
Azab, Mohammad Dr. Mohammad Azab, M.D., M Sc, MBA., is Chief Medical Officer of SuperGen Inc. With more than 20 years of experience in worldwide drug development, clinical research, and medical affairs, resulting in eight approved drugs, including six in oncology, Dr. Azab brings extensive, international development and translational medicine expertise to SuperGen. Most recently, he was President and CEO of Intradigm Corporation, a privately held Palo Alto, CA company developing siRNA cancer therapeutics. Previously, Dr. Azab served as Executive Vice President of Research and Development, and Chief Medical Officer, of Vancouver, British Columbia-based QLT Inc., where he led clinical development for now-approved drugs in oncology, gastro-intestinal, and ophthalmologic indications. Prior to this, he served as Oncology Drug Team Leader at UK-based Zeneca Pharmaceuticals, now Astra Zeneca, where he held responsibilities in global clinical development and regulatory submissions. In this capacity, he managed the approval of drugs for prostate, breast, colorectal, and lung cancer indications. Before Zeneca Dr. Azab was an international medical manager in oncology at Sanofi Pharmaceuticals, now Sanofi-Aventis, in Gentilly, France. Dr. Azab received his medical degree in 1979 from Cairo University. He practiced as a medical oncologist and received post-graduate training and degrees in oncology research and statistics from the University of Paris-Sud and the University of Pierre and Marie Curie in France. He has published more than 100 medical papers and abstracts. He is an active member of the American Society of Clinical Oncology, the American Association of Cancer Research, and the European Society of Medical Oncology. Dr. Azab received an Master of Business Administration, with Distinction, from the Richard Ivey School of Business, University of Western Ontario.
Girardi, Thomas Mr. Thomas V. Girardi is Director of SuperGen Inc since May 2000. Mr. Girardi is senior partner of Girardi & Keese, a law firm specializing in major business litigation, where he has worked since 1964. Mr. Girardi has served as national president and Los Angeles chapter president of the American Board of Trial Advocates, has also served as president of the International Academy of Trial Lawyers, an organization limited to 500 trial lawyers in America, 2005 to 2006 and is a member of the Inner Circle of Advocates, American Board of Professional Liability Lawyers, International Society of Barristers, and American Trial Lawyers Association. Mr. Girardi is also a member of the board of directors of Boyd Gaming, Inc. He received his B.S. from Loyola Marymount University, his J.D. from Loyola Law School and an L.L.M. from New York University.
Lack, Walter Mr. Walter J. Lack is Director of SuperGen Inc since February 2000. Mr. Lack is managing partner of Engstrom, Lipscomb & Lack, a Los Angeles, California law firm that he founded in 1974. Mr. Lack has acted as a special arbitrator for the Superior Court of the State of California since 1976 and for the American Arbitration Association since 1979. He is a member of the International Academy of Trial Lawyers and an Advocate of the American Board of Trial Advocates. He received his B.A. from Loyola Marymount University where he is a long standing member of the Board of Regents. He received his J.D. from Loyola Law School in Los Angeles.
Young, Michael Mr. Michael D. Young, M.D., Ph.D. is Director of SuperGen Inc since September 2002. Dr. Young has more than 25 years of experience in the pharmaceutical industry, with significant management experience in the areas of clinical research and development, pre-clinical development and worldwide regulatory affairs. Prior to joining the board of directors, he served as development director, chief scientific officer, for London-based Celltech PLC, a European biotechnology company, where he was responsible for all research and strategic product development. During his tenure, Celltech developed five new products. Previously, Dr. Young was corporate director, worldwide regulatory and clinical development, for The Procter & Gamble Company. He has also held senior positions at SmithKline Beckman Corp., French Laboratories, Astra Pharmaceuticals and Delbay Pharmaceuticals (a joint-venture between Bayer and Schering Plough).
Casamento, Charles Mr. Charles J. Casamento is Director of SuperGen Inc. since September 2002. Mr. Casamento is currently Executive Director and Principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies. Mr. Casamento was the president and CEO of Osteologix, Inc., a public biopharmaceutical company developing products for treating osteoporosis, from 2004 through 2007. From 1999 through 2004, he served as chairman of the board, president and CEO of Questcor Pharmaceuticals, Inc. Mr. Casamento formerly served as RiboGene, Inc.'s president, CEO and chairman of the board from 1993 through 1999 until it merged with Cypros to form Questcor. He was co-founder, president and CEO of Interneuron Pharmaceuticals, Inc., a biopharmaceutical company, from 1989 until 1993. Mr. Casamento has also held senior management positions at Genzyme Corporation, where he was senior vice president, pharmaceuticals and biochemicals; American Hospital Supply, where he was vice president of business development and strategic planning for the Critical Care Division; Johnson & Johnson, Hoffmann-LaRoche, Inc. and Sandoz Inc. Mr. Casamento also serves on the Boards of Directors of CORTEX Pharmaceuticals and VIVUS, Inc. He holds a bachelor's degree in Pharmacy from Fordham University and an M.B.A. from Iona College and is a licensed pharmacist in the states of New York and New Jersey.
Goldberg, Allan Mr. Allan R. Goldberg, Ph.D. is Director of SuperGen Inc since March 2005. Dr. Goldberg is a co-founder and currently serves as a managing partner of The Channel Group LLC (TCG), a global life sciences venture management and strategic advisory organization with expertise in business, financial, and commercial development. Prior to his affiliation with TCG, Dr. Goldberg co-founded PrimeTech Partners, a venture management partnership whose purpose was to create, finance and develop biomedical companies. From 1989 to 1997, Dr. Goldberg held various senior management positions including chief scientific officer, chairman and chief executive officer at Innovir Laboratories, Inc., a NASDAQ-listed biotechnology company he co-founded. He currently is a director and co-founder of ZyStor Therapeutics, Inc., a Milwaukee-based biotechnology company. In addition, he also is on the Board of Directors of LCT BioPharma Inc., the U.S. subsidiary of Living Cell Technologies Limited (ASX:LCT), and of Lesanne Life Sciences, LLC. Prior to Innovir, Dr. Goldberg was a professor of virology and a Richard King Mellon Foundation Fellow at The Rockefeller University from 1971 to 1989. Dr. Goldberg has served as a consultant to several large pharmaceutical companies as well as numerous private and public academic institutions. He earned a B.A. in English and Mathematics from Cornell University and a Ph.D. in Biochemistry/Biology from Princeton University, and was a postdoctoral fellow at Albert Einstein College of Medicine.

Basic Compensation

Name Fiscal Year Total
Manuso, James 2,533,320
Molkentin, Michael 560,232
Azab, Mohammad --
Girardi, Thomas --
Lack, Walter --
Young, Michael --
Casamento, Charles --
Goldberg, Allan --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Manuso, James 1,718,000 273,650
Molkentin, Michael 125,000 4,000
Azab, Mohammad 0 0
Girardi, Thomas 0 0
Lack, Walter 0 0
Young, Michael 0 0
Casamento, Charles 0 0
Goldberg, Allan 0 0

Insider Trading

Name Shares Traded Price
NB PUBLIC EQUITY KS 1,509 $2.39
NB PUBLIC EQUITY KS 48,391 $2.40
NB PUBLIC EQUITY KS 100 $2.40
NB PUBLIC EQUITY KS 100 $2.92
NB PUBLIC EQUITY KS 2,200 $2.96
NB PUBLIC EQUITY KS 800 $2.93
NB PUBLIC EQUITY KS 63,282 $2.98
NB PUBLIC EQUITY KS 4,900 $2.95
NB PUBLIC EQUITY KS 100 $2.93
NB PUBLIC EQUITY KS 1,700 $2.97
NB PUBLIC EQUITY KS 5,056 $2.94
NB PUBLIC EQUITY KS 34,955 $2.89
NB PUBLIC EQUITY KS 1,400 $2.88
NB PUBLIC EQUITY KS 1,000 $2.86
NB PUBLIC EQUITY KS 8,838 $2.88
NB PUBLIC EQUITY KS 800 $2.85
NB PUBLIC EQUITY KS 706 $2.87
NB PUBLIC EQUITY KS 12,356 $2.89
NB PUBLIC EQUITY KS 325 $2.87
NB PUBLIC EQUITY KS 100 $2.88
NB PUBLIC EQUITY KS 6,975 $2.88
NB PUBLIC EQUITY KS 100 $2.88
NB PUBLIC EQUITY KS 100 $2.87
NB PUBLIC EQUITY KS 100 $2.86
NB PUBLIC EQUITY KS 4,100 $2.87
» Full list on Insider Trading
view people for: